Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 3/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.55 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11478144 | 1.00 | BLM (0.58) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL29833669 | 1.00 | BLM (0.58) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL8773315 | 0.84 | BLM (0.60) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL4629339 | 0.83 | DPP4 (0.40) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL709482 | 0.82 | GRM8 (0.60) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL1534041 | 0.82 | CTSD (0.44) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL709483 | 0.82 | GRM8 (0.60) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL1534035 | 0.82 | CTSD (0.44) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL308629 | 0.82 | CTSD (0.44) | BLMALOX15PMP22KMT2ADPP4 | |
| SCHEMBL21447963 | 0.82 | BLM (0.58) | BLMALOX15PMP22KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425817-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024032822-A1 | IMPROVED ANTIBODY SPECIFICALLY BINDING TO AMYLOID-β OLIGOMERS | 深圳智源生物医药有限公司 | 2024-02-15 | — | — | WO | disclosed |
| EP-4271399-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023092743-A1 | METHOD FOR REGULATING HYDROXYLATION OF RECOMBINANT PROTEIN AND USE THEREOF | 佛山汉腾生物科技有限公司 | 2023-06-01 | — | — | WO | disclosed |
| CN-115243780-A | Filter material | 东丽株式会社 | 2022-10-25 | — | — | CN | disclosed |
| WO-2022147056-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-110196288-A | A kind of foundation and application of dynamic Metabolic flux analysis technology | 中国科学院上海生命科学研究院 | 2019-09-03 | — | — | CN | disclosed |
| EP-2427446-B1 | INHIBITORS OF SIALIDASE OR SIALIDASE-LIKE ENZYMES | NAT RES COUNCIL CANADA (CA) | 2016-03-30 | — | — | EP | disclosed |
| US-9169339-B2 | Curable composition, molded product and method for producing molded product | DAIKIN INDUSTRIES, LTD. (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169339-B2 | Curable composition, molded product and method for producing molded product | DAIKIN INDUSTRIES, LTD. (JP) | 2015-10-27 | — | — | US | disclosed |
| EP-2427446-A1 | INHIBITORS OF SIALIDASE OR SIALIDASE-LIKE ENZYMES | National Research Council of Canada (CA) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046355-A1 | INHIBITORS OF SIALIDASE OR SIALIDASE-LIKE ENZYMES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2012-02-23 | — | — | US | disclosed |
| US-7842460-B2 | Method for assessing proteolytic enzyme activity using ubiquitin fusion substrate | PROGENRA INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-1792181-B1 | DIAGNOSTIC AND SCREENING METHODS AND KITS ASSOCIATED WITH PROTEOLYTIC ACTIVITY | PROGENRA INC (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2010127443-A1 | INHIBITORS OF SIALIDASE OR SIALIDASE-LIKE ENZYMES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-11-11 | — | — | WO | disclosed |
| EP-1792181-A4 | DIAGNOSTIC AND SCREENING METHODS AND KITS ASSOCIATED WITH PROTEOLYTIC ACTIVITY | PROGENRA INC (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1792181-A2 | DIAGNOSTIC AND SCREENING METHODS AND KITS ASSOCIATED WITH PROTEOLYTIC ACTIVITY | Progenra Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20060040335-A1 | Diagnostic and screening methods and kits associated with proteolytic activity | PROGENRA INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006002100-A2 | DIAGNOSTIC AND SCREENING METHODS AND KITS ASSOCIATED WITH PROTEOLYTIC ACTIVITY | PROGENRA INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-4219650-A | REACTION OF L-GLUTAMIC ACID ESTER METAL COMPLEX WITH A DIAMINE | CIBA-GEIGY CORPORATION (US) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046355-A1 | INHIBITORS OF SIALIDASE OR SIALIDASE-LIKE ENZYMES | NEU2, NEU1, NEU3 | BLM 4350/4885ALOX15 524/4885PMP22 2497/4885 |
| US-20240425817-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | IAPP, AMY2A, CEL | BLM 1643/4885ALOX15 3099/4885PMP22 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.